- Home
- CAPT vs LYRA Comparison
CAPT vs LYRA Comparison
Compare CAPT & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- LYRA
- Stock Information
- Founded
- CAPT 2005
- LYRA 2005
- Country
- CAPT South Korea
- LYRA United States
- Employees
- CAPT N/A
- LYRA N/A
- Industry
- CAPT Blank Checks
- LYRA Medical/Dental Instruments
- Sector
- CAPT Finance
- LYRA Health Care
- Exchange
- CAPT Nasdaq
- LYRA Nasdaq
- Market Cap
- CAPT 16.0M
- LYRA 15.0M
- IPO Year
- CAPT N/A
- LYRA 2020
- Fundamental
- Price
- CAPT $1.54
- LYRA $8.68
- Analyst Decision
- CAPT
- LYRA Buy
- Analyst Count
- CAPT 0
- LYRA 2
- Target Price
- CAPT N/A
- LYRA $16.00
- AVG Volume (30 Days)
- CAPT 357.6K
- LYRA 153.4K
- Earning Date
- CAPT 01-01-0001
- LYRA 08-13-2025
- Dividend Yield
- CAPT N/A
- LYRA N/A
- EPS Growth
- CAPT N/A
- LYRA N/A
- EPS
- CAPT N/A
- LYRA N/A
- Revenue
- CAPT $17,389,944.00
- LYRA $1,185,000.00
- Revenue This Year
- CAPT N/A
- LYRA N/A
- Revenue Next Year
- CAPT N/A
- LYRA $1,286.17
- P/E Ratio
- CAPT N/A
- LYRA N/A
- Revenue Growth
- CAPT 84.70
- LYRA N/A
- 52 Week Low
- CAPT $0.37
- LYRA $3.81
- 52 Week High
- CAPT $2.88
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- CAPT 71.95
- LYRA 44.53
- Support Level
- CAPT $1.14
- LYRA $8.69
- Resistance Level
- CAPT $1.21
- LYRA $9.36
- Average True Range (ATR)
- CAPT 0.08
- LYRA 0.96
- MACD
- CAPT 0.02
- LYRA -0.41
- Stochastic Oscillator
- CAPT 86.54
- LYRA 10.87
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.